ILCA 2023 | Molecular typing based on fatty acid degradation metabolism helps in achieving precision treatment for liver cancer.

ILCA 2023 | Molecular typing based on fatty acid degradation metabolism helps in achieving precision treatment for liver cancer.

2024.02.14
Primary liver cancer is currently the 4th most common malignant tumor and the 2nd leading cause of tumor-related death in China. 75%~85% of these cases are Hepatocellular carcinoma (HCC), posing a serious threat to the health and lives of Chinese citizens. In recent years, with the progress in traditional therapies like surgery, intervention, radiation, targeted therapy, and immunotherapy, there are now more options available for liver cancer patients. Recent clinical studies have shown that the combined treatment plan of atezolizumab and bevacizumab (referred to as “T+A”) can reduce the mortality risk of advanced liver cancer patients by 42% compared to the traditional targeted drug sorafenib, setting a new standard for the first-line treatment of advanced liver cancer. However, the overall survival rate of liver cancer patients remains unsatisfactory, with a 5-year survival rate of about 20%. Due to the heterogeneity of liver cancer, there is still a significant variance in the treatment response and prognosis of patients with the same clinical stage. How to select the most suitable individualized treatment method for different liver cancer patients, to maximize therapeutic effects, is a pressing issue in the clinic.
ILCA Expert Interview | Moving Forward Together! The Development and Prospects of Multidisciplinary Comprehensive Treatment of Liver Cancer

ILCA Expert Interview | Moving Forward Together! The Development and Prospects of Multidisciplinary Comprehensive Treatment of Liver Cancer

2024.02.14
Primary liver cancer is one of the common malignant tumors worldwide. With the development of modern biomedical technology, clinical surgical techniques, and minimally invasive treatment techniques, the surgical treatment level of liver cancer has made significant progress. At the recently concluded global academic event in the field of liver cancer - the 17th Annual Meeting of the International Liver Cancer Association (ILCA), Professor Myron Schwartz of Mount Sinai Hospital in the U.S. delivered a keynote report on the progress made in liver cancer surgical treatment in recent years. Our journal specially invited Professor Myron Schwartz for an in-depth interview on the evolution of future liver cancer clinical treatment strategies and the opportunities and challenges that liver cancer surgery will face. Here is the organized content for our readers.
Dr. Dong Hsu: Meeting More Patient Needs in HIV Health Management

Dr. Dong Hsu: Meeting More Patient Needs in HIV Health Management

2024.02.14
Implementation Science is a relatively new and increasingly recognized field of research. Its purpose is to translate the possibilities outlined in theory into practical applications in the real world, addressing the challenges of implementing validated intervention measures. At the 2023 APACC conference, Dr. Dong Hsu, from the School of Public Health Management and the Global Health Research Center, Southern Medical University, China, delivered an insightful presentation titled "Implementation of Clinical Practice Guidelines". In our interview, Dr. Dong Hsu further elaborated on the definition and research value of Implementation Science and shared his team's research findings in areas such as HIV screening and health management.
ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

ESMO 2023丨Andrea Nccchi: Novel Intravesical Drug Delivery System Helps Bladder Cancer Patients Preserve Bladder, Reduce Risk of Recurrence

2024.02.14
At the 2023 European Society of Medical Oncology (ESMO 2023), Dr. Andrea Nccchi reported a phase 2b clinical study at the mini oral presentation, using a new intravesical local chemotherapy delivery system. TAR200 is expected to become a treatment method for patients with high-risk non-muscle invasive bladder (HR MIBC) to reduce disease recurrence. In addition, ESMO 2023 also reported TAR201 and EV-302 study. Dr. Andrea Nccchi shared his views on these latest studies in an interview with " Oncology Frontier ".
WCLC Interview | Dr. Baohui Han: Discussion and Prospects of Hot Topics in Targeted Therapy of Lung Cancer

WCLC Interview | Dr. Baohui Han: Discussion and Prospects of Hot Topics in Targeted Therapy of Lung Cancer

2024.02.13
The 2023 World Conference on Lung Cancer (WCLC), held from September 9th to 12th at the Singapore, provided a platform for oncology experts to delve into cutting-edge developments. The “Oncology Frontier” team reports on-the-spot international cutting-edge developments and witnesses the progress of China's anti-cancer cause on the international stage. Renowned oncologist Dr. Baohui Han, from the Shanghai Chest Hospital, delivered a significant address at the conference. In an exclusive interview with “Oncology Frontier”, Dr. Han shared profound insights into the latest breakthroughs and contemplations on hot topics in targeted therapy for lung cancer.
2023 WCLC | Dr. Caicun Zhou Discusses Latest Results on EGFR exon20ins Mutation

2023 WCLC | Dr. Caicun Zhou Discusses Latest Results on EGFR exon20ins Mutation

2024.02.13
The World Conference on Lung Cancer (WCLC), a significant academic exchange event in the global lung cancer field, was successfully held in Singapore from September 9 to 12, 2023. The conference revealed many important research findings, bringing about a new era of treatment in clinical practice. Among them, the EGFR Exon20 insertion mutation (EGFR exon20ins) as the third major EGFR mutation has garnered widespread attention. In recent years, novel treatments for this mutation have continuously emerged. At the WCLC, the phase 1b results of the FAVOUR study on the treatment of EGFR exon20ins-positive advanced non-small cell lung cancer (NSCLC) with furmonertinib were reported. " Oncology Frontier " had the privilege of interviewing Dr. Caicun Zhou, a leading figure in the field of lung cancer treatment at Shanghai Pulmonary Hospital and Tongji University School of Medicine. Dr. Zhou shared the latest treatments of EGFR exon20ins-positive NSCLC.